Shu-Pin Huang, Bo-Ying Bao, Ta-Hsien Chuang, Chao-Yuan Huang, Chia-Cheng Yu, Victor C Lin, Te-Ling Lu, Yei-Tsung Chen
{"title":"Prognostic Significance of <i>EZH2</i>-Related Gene Variants in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy.","authors":"Shu-Pin Huang, Bo-Ying Bao, Ta-Hsien Chuang, Chao-Yuan Huang, Chia-Cheng Yu, Victor C Lin, Te-Ling Lu, Yei-Tsung Chen","doi":"10.21873/cgp.20525","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Prostate cancer remains a major global health burden, with treatment resistance posing a significant challenge. Enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), a histone methyltransferase, is frequently overexpressed in prostate cancer, contributing to tumor progression and castration resistance. Clinical trials of EZH2 inhibitors may have therapeutic benefits. This study aimed to evaluate the impact of genetic variants in <i>EZH2</i>-related genes on survival outcomes in prostate cancer.</p><p><strong>Patients and methods: </strong>We conducted a genetic association study evaluating 76 single nucleotide polymorphisms (SNPs) across 10 <i>EZH2</i>-related genes in 630 patients with prostate cancer undergoing androgen deprivation therapy (ADT). Functional analyses, including gene ontology and pathway enrichment assessments, were performed to elucidate the biological significance of key genes across multiple datasets.</p><p><strong>Results: </strong><i>DNMT3A</i> rs77993651 was significantly associated with both cancer-specific survival [hazard ratio (HR)=0.82, <i>p</i>=0.042] and overall survival (HR=0.80, <i>p</i>=0.011). Functional annotation indicated that rs77993651 resides within enhancer histone marks, potentially regulating <i>DNMT3A</i> expression. Elevated <i>DNMT3A</i> expression was observed in prostate tumor tissues and correlated with more aggressive features and shorter progression-free survival. Gene set enrichment analysis revealed that <i>DNMT3A</i> expression was strongly associated with cell cycle G<sub>2</sub>/M checkpoint regulation, implicating a role in prostate cancer progression.</p><p><strong>Conclusion: </strong>The prognostic significance of <i>DNMT3A</i> and its genetic variant rs77993651 in prostate cancer is herein highlighted. Targeting <i>DNMT3A</i>-mediated pathways may offer novel therapeutic strategies for prostate cancer management.</p>","PeriodicalId":9516,"journal":{"name":"Cancer Genomics & Proteomics","volume":"22 4","pages":"611-623"},"PeriodicalIF":2.6000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12216571/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Genomics & Proteomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/cgp.20525","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: Prostate cancer remains a major global health burden, with treatment resistance posing a significant challenge. Enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), a histone methyltransferase, is frequently overexpressed in prostate cancer, contributing to tumor progression and castration resistance. Clinical trials of EZH2 inhibitors may have therapeutic benefits. This study aimed to evaluate the impact of genetic variants in EZH2-related genes on survival outcomes in prostate cancer.
Patients and methods: We conducted a genetic association study evaluating 76 single nucleotide polymorphisms (SNPs) across 10 EZH2-related genes in 630 patients with prostate cancer undergoing androgen deprivation therapy (ADT). Functional analyses, including gene ontology and pathway enrichment assessments, were performed to elucidate the biological significance of key genes across multiple datasets.
Results: DNMT3A rs77993651 was significantly associated with both cancer-specific survival [hazard ratio (HR)=0.82, p=0.042] and overall survival (HR=0.80, p=0.011). Functional annotation indicated that rs77993651 resides within enhancer histone marks, potentially regulating DNMT3A expression. Elevated DNMT3A expression was observed in prostate tumor tissues and correlated with more aggressive features and shorter progression-free survival. Gene set enrichment analysis revealed that DNMT3A expression was strongly associated with cell cycle G2/M checkpoint regulation, implicating a role in prostate cancer progression.
Conclusion: The prognostic significance of DNMT3A and its genetic variant rs77993651 in prostate cancer is herein highlighted. Targeting DNMT3A-mediated pathways may offer novel therapeutic strategies for prostate cancer management.
期刊介绍：
Cancer Genomics & Proteomics (CGP) is an international peer-reviewed journal designed to publish rapidly high quality articles and reviews on the application of genomic and proteomic technology to basic, experimental and clinical cancer research. In this site you may find information concerning the editorial board, editorial policy, issue contents, subscriptions, submission of manuscripts and advertising. The first issue of CGP circulated in January 2004.
Cancer Genomics & Proteomics is a journal of the International Institute of Anticancer Research. From January 2013 CGP is converted to an online-only open access journal.
Cancer Genomics & Proteomics supports (a) the aims and the research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
